Ascendis Pharma A/S
ASND
Kedudukan dalam Saham
#1550
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Harga Saham
$224.87
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$14.03B
Perubahan (1 hari)
-0.77%
Perubahan (1 tahun)
6.83%
Negara
DK
Perdagangan Ascendis Pharma A/S (ASND)
Kategori
Healthcare
EPS untuk Ascendis Pharma A/S (ASND)
EPS setakat June 2026 TTM: $14.35
Menurut laporan kewangan terkini dan harga saham Ascendis Pharma A/S, EPS semasa syarikat (TTM) adalah $14.35. Pada akhir tahun 2024, syarikat mempunyai EPS sebanyak $-6.79 penurunan berbanding EPS tahun 2023 iaitu $-9.45.
Sejarah EPS untuk Ascendis Pharma A/S dari 2012 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $14.35 | -437.71% |
| 2025 | $-4.25 | -37.49% |
| 2024 | $-6.79 | -28.11% |
| 2023 | $-9.45 | -15.28% |
| 2022 | $-11.16 | 40.15% |
| 2021 | $-7.96 | -21.06% |
| 2020 | $-10.08 | 91.63% |
| 2019 | $-5.26 | 44.45% |
| 2018 | $-3.64 | -17.50% |
| 2017 | $-4.42 | 62.66% |
| 2016 | $-2.71 | 79.86% |
| 2015 | $-1.51 | 118.83% |
| 2014 | $-0.69 | -231.97% |
| 2013 | $0.52 | 230.13% |
| 2012 | $0.16 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | 20.68% |
US
|
|
| $-7.98 | -155.60% |
US
|
|
| $-5.29 | -136.86% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 93.28% |
NL
|
